- Dulaglutide (Trulicity) and semaglutide (Ozempic, Wegovy, Rybelsus) are both GLP-1 receptor agonists, but they are approved for different uses — Trulicity is a type 2 diabetes and cardiovascular drug, not a weight-loss drug.
- In the head-to-head SUSTAIN-7 trial, semaglutide produced a modestly greater A1C reduction and more weight loss than dulaglutide; higher dulaglutide doses narrowed but did not close the gap.
- Semaglutide comes as a weekly injection (Ozempic, Wegovy) and an oral tablet (Rybelsus); dulaglutide is a once-weekly injection only, in a simpler auto-injector.
- Both carry a boxed warning for thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
- Dosing and any dose changes must be directed by your prescriber — never copy a titration schedule from an article or from another patient.
- Neither drug is universally "better"; the right choice depends on your diagnosis, insurance coverage, tolerance, device preference, and clinical goals.
In the head-to-head SUSTAIN-7 trial, semaglutide produced a 0.4 percentage-point greater A1C reduction and roughly 3 kilograms more weight loss than dulaglutide over 40 weeks — a meaningful but not overwhelming margin. Dulaglutide vs semaglutide is a practical decision many patients with type 2 diabetes face when their prescriber is weighing once-weekly GLP-1 options, and the choice depends on more than peak efficacy. Insurance coverage, tolerability, dosing flexibility, and patient preference around drug administration all factor in. This guide walks through what the trials actually show and how the two drugs compare in real-world practice. Nothing here is a prescription or a dosing plan — it is general education, and every decision below belongs to you and your clinician. For broader context, see our medical conditions guide.
Same Drug Class, Different Jobs
Before comparing numbers, it helps to be precise about what each product is approved to do, because the two names are not interchangeable. Dulaglutide and semaglutide are both GLP-1 receptor agonists, but the FDA has cleared them for different indications, and confusing the two leads people to expect the wrong outcome.
| Feature | Dulaglutide | Semaglutide |
|---|---|---|
| Brand names | Trulicity | Ozempic, Wegovy, Rybelsus |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Approved for type 2 diabetes | Yes (Trulicity) | Yes (Ozempic, Rybelsus) |
| Approved for chronic weight management | No | Yes (Wegovy only) |
| Cardiovascular risk-reduction labeling | Yes (Trulicity) | Yes (Ozempic, Wegovy) |
| Forms available | Weekly injection | Weekly injection and daily oral tablet |
| Boxed thyroid C-cell tumor warning | Yes | Yes |
The single most important accuracy point: Trulicity is not a weight-loss drug. It is approved for glycemic control in type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors. Patients often lose some weight on it, but weight loss is not an approved indication. Within the semaglutide family, only Wegovy is approved for chronic weight management; Ozempic and Rybelsus are diabetes products. Using any of them for weight is a decision only a prescriber can make.
What Each Drug Is
Dulaglutide is sold as Trulicity by Eli Lilly. It is a once-weekly subcutaneous injection that activates the GLP-1 receptor. Approved by the FDA in 2014 for adults with type 2 diabetes, it also received expanded labeling for cardiovascular risk reduction in patients with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
Semaglutide is sold as Ozempic (injectable, for diabetes), Wegovy (higher-dose injectable, for obesity and, more recently, for cardiovascular risk reduction in adults with established heart disease who are overweight or obese), and Rybelsus (oral tablet, for diabetes) by Novo Nordisk. Injectable semaglutide was FDA-approved in 2017 for type 2 diabetes. Novo Nordisk has also expanded semaglutide’s label over time into additional cardiovascular and kidney-related uses; because these indications keep evolving, verify the current approved uses for any specific product with your prescriber or the FDA label. See our GLP-1 vs Ozempic comparison for more on the semaglutide family.
Mechanism Similarities and Differences
Both dulaglutide and semaglutide are GLP-1 receptor agonists. They share a common mechanism: activating GLP-1 receptors to slow gastric emptying, reduce appetite, and improve glucose-dependent insulin secretion. Both are engineered to resist the rapid degradation that destroys endogenous GLP-1, allowing once-weekly injectable dosing.
The molecules are structurally different, however. Dulaglutide is a fusion protein combining a modified GLP-1 analog with an immunoglobulin fragment that slows renal clearance. Semaglutide is a modified peptide with amino acid substitutions and a fatty acid chain that binds albumin, extending circulating half-life. The practical result of these engineering differences is that semaglutide tends to achieve somewhat stronger GLP-1 receptor activation at its target doses, which appears to translate to modestly greater efficacy outcomes in the trials to date.
A1C Reduction: The SUSTAIN-7 Head-to-Head
The SUSTAIN-7 trial directly compared semaglutide 1.0 mg weekly to dulaglutide 1.5 mg weekly over 40 weeks. Semaglutide produced an A1C reduction of about 1.8 percentage points, while dulaglutide produced about 1.4 percentage points. Both reductions are clinically meaningful, but the head-to-head margin favored semaglutide by roughly 0.4 percentage points.
Since SUSTAIN-7, dulaglutide has been approved at higher doses (3.0 mg and 4.5 mg weekly), which narrows but does not fully close the efficacy gap with semaglutide. The AWARD-11 trial of higher-dose dulaglutide showed A1C reductions approaching those seen with semaglutide 1.0 mg, though direct head-to-head trials of the newer dulaglutide doses against semaglutide have not been conducted, so cross-trial comparisons should be read cautiously.
Weight Loss Comparison
In SUSTAIN-7, semaglutide 1.0 mg weekly produced an average weight loss of about 6.5 kilograms, compared with about 3.0 kilograms on dulaglutide 1.5 mg over 40 weeks. At the higher Ozempic dose of 2.0 mg weekly (approved after SUSTAIN-7), semaglutide produces even greater weight loss, and Wegovy — dosed higher still and studied specifically for obesity — produces the largest average reductions in the semaglutide family.
Dulaglutide’s higher doses (3.0 and 4.5 mg) improved its weight-related outcomes, with the 4.5 mg dose producing roughly 4.7 kilograms of loss in AWARD-11. Across the available data, semaglutide generally produces greater average weight change than dulaglutide. But remember the framing from earlier: weight change on Trulicity is a secondary effect, not an approved use. For patients whose clinical goal is weight management, the appropriate GLP-1 conversation is about Wegovy or another approved anti-obesity medicine, not Trulicity — and neither semaglutide product matches tirzepatide’s weight-loss outcomes in trials. Compare in our GLP-1 weight loss guide.
Cardiovascular Outcomes
Both drugs carry cardiovascular risk-reduction labeling based on large outcomes trials. The REWIND trial for dulaglutide showed roughly a 12 percent reduction in major adverse cardiovascular events in patients with type 2 diabetes and either established cardiovascular disease or multiple risk factors. The SUSTAIN-6 trial for semaglutide showed roughly a 26 percent reduction in MACE in patients with type 2 diabetes and established cardiovascular disease.
Indirect comparison suggests semaglutide’s cardiovascular risk reduction may be somewhat stronger, but the trial populations differed (REWIND included many primary-prevention patients, while SUSTAIN-6 was predominantly secondary prevention), so a direct “one beat the other” conclusion is not supported. Both drugs are considered strong options for patients with type 2 diabetes and cardiovascular disease per the American Diabetes Association Standards of Care.
Side Effect Profiles
Gastrointestinal side effects dominate both drugs’ profiles. Nausea, vomiting, diarrhea, constipation, and abdominal pain are the most commonly reported. In SUSTAIN-7, nausea affected about 22 percent of patients on semaglutide versus about 14 percent on dulaglutide — a meaningful difference, though dulaglutide at its higher doses produces higher nausea rates than it did at 1.5 mg.
Beyond GI effects, both drugs share warnings about pancreatitis, gallbladder disease, acute kidney injury (often triggered by dehydration from vomiting or diarrhea), and worsening of diabetic retinopathy in some patients. Both can also increase the risk of low blood sugar when combined with insulin or sulfonylureas. Injection-site reactions are uncommon with either drug. Report severe or persistent abdominal pain, signs of an allergic reaction, or vision changes to a clinician promptly.
The GLP-1 Thyroid Boxed Warning
Both dulaglutide (Trulicity) and semaglutide (Ozempic, Wegovy, Rybelsus) carry the FDA’s most serious warning, a boxed warning, for the risk of thyroid C-cell tumors. In rodent studies these drugs caused thyroid tumors, including medullary thyroid carcinoma (MTC); whether they cause these tumors in humans is not known. Because of this risk, they are contraindicated — meaning they should not be used — in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your prescriber about any family history of thyroid cancer, and seek care for symptoms such as a neck lump or mass, trouble swallowing, shortness of breath, or persistent hoarseness. This is general education, not medical advice.
Convenience and Administration
Dulaglutide is delivered in single-use auto-injector pens that require no dose dialing or needle attachment — the patient simply presses the device against skin and activates it. Semaglutide’s injectable pen typically requires more steps: for some products, attaching a needle and confirming or dialing the dose before administering. For patients with dexterity issues, vision problems, or injection anxiety, dulaglutide’s simpler device often wins preference.
Semaglutide is also available in oral form as Rybelsus, which eliminates injections entirely but requires strict administration rules (taken on an empty stomach with a small sip of plain water, at least 30 minutes before any other food, drink, or medication). Dulaglutide has no oral version. For patients strongly preferring an oral option, Rybelsus is the diabetes choice in this class. Any titration — the gradual step-up in dose used to limit nausea — is set and adjusted by your prescriber; do not copy a schedule from an article, a forum, or another patient, and do not change your dose on your own.
Cost Comparison
Both injectable products list at broadly similar prices, generally in the four-figures-per-month range at wholesale acquisition cost before any insurance or discounts. List prices change frequently, so treat any specific number as an estimate and verify current pricing at the pharmacy or with the manufacturer. Commercial insurance coverage is often similar for the diabetes indications, with many plans that cover one covering the other; coverage for weight management (Wegovy) is far more restricted and varies widely by plan.
Manufacturer savings cards from Lilly (Trulicity) and Novo Nordisk (Ozempic, Wegovy, Rybelsus) can reduce copays for eligible commercially insured patients, but the exact copay floor and monthly maximum change over time and differ by product, so confirm the current terms on the official manufacturer pages. Savings cards generally exclude Medicare, Medicaid, and other government beneficiaries. For detailed coupon rules see our Rybelsus coupon guide.
Frequently Asked Questions
Is dulaglutide or semaglutide more effective for diabetes?
Semaglutide produced slightly greater A1C reduction than dulaglutide in head-to-head data (about 1.8 versus 1.4 percentage points in SUSTAIN-7). Both are effective, and individual response varies — many patients achieve excellent glucose control on either drug. Your prescriber weighs efficacy alongside tolerance, other conditions, and coverage.
Which causes more weight loss, dulaglutide or semaglutide?
Semaglutide produced greater average weight loss in head-to-head trials (about 6.5 kg versus 3.0 kg in SUSTAIN-7 at the doses studied). Higher doses of dulaglutide approved after SUSTAIN-7 narrowed the gap but did not eliminate it. Note that only Wegovy (a semaglutide product) is approved specifically for weight management; Trulicity is not.
Is Trulicity approved for weight loss?
No. Dulaglutide (Trulicity) is approved for blood-sugar control in type 2 diabetes and for cardiovascular risk reduction in adults with type 2 diabetes and heart disease or risk factors. Weight change can occur but is not an approved use. If weight management is your goal, ask your clinician about medications that are approved for it.
Can you switch from dulaglutide to semaglutide?
Yes, and patients commonly do so under a prescriber’s guidance for better glucose control or a different indication. When switching, prescribers typically restart at the lowest introductory dose of the new drug to allow tolerance to build, regardless of your prior dulaglutide dose. Do not attempt to convert doses yourself.
Are side effects worse on dulaglutide or semaglutide?
SUSTAIN-7 showed slightly higher nausea rates with semaglutide (about 22 percent versus 14 percent). Individual responses vary, and both drugs share the same overall side-effect profile typical of the GLP-1 class, including the boxed thyroid warning and pancreatitis and gallbladder cautions.
Is dulaglutide or semaglutide easier to use?
Dulaglutide’s auto-injector pen requires no needle attachment or dose dialing, making it simpler for patients with dexterity or vision challenges. Semaglutide’s injectable pen requires more preparation steps but is also available as an oral tablet (Rybelsus) for patients who prefer pills over injections.
The Bottom Line on Dulaglutide vs Semaglutide
Semaglutide generally produces slightly greater A1C reduction and weight change than dulaglutide at comparable doses, while dulaglutide offers a simpler injection device and a solid cardiovascular benefit. Both are effective once-weekly GLP-1 options for type 2 diabetes — but they are not the same product, and only Wegovy (semaglutide) is approved for weight management. The decision often comes down to your diagnosis, insurance coverage, individual tolerance, and personal preference around the injection device or an oral alternative. Talk with your prescriber about which matches your specific goals; neither is categorically “better,” and many patients achieve strong outcomes on either drug.
This article is general education and is not medical advice. GLP-1 medicines are prescription drugs with a boxed thyroid warning, important contraindications, and side effects; the right drug, dose, and titration depend on your diagnosis, health history, and other medicines, and must be decided with a qualified clinician. Do not start, stop, switch, or adjust any medication based on this article, and verify current indications and prices with the manufacturer or FDA.
Sources
- MedlinePlus (U.S. National Library of Medicine) — Semaglutide and Dulaglutide drug information: indications, once-weekly dosing, boxed thyroid C-cell tumor warning, MEN2 contraindication, and adverse effects
- U.S. Food and Drug Administration (FDA) / DailyMed — Trulicity (dulaglutide) and Ozempic, Wegovy, and Rybelsus (semaglutide) prescribing information and boxed warnings
- SUSTAIN-7, The Lancet Diabetes & Endocrinology — head-to-head semaglutide vs dulaglutide (A1C and weight outcomes)
- AWARD-11 — higher-dose dulaglutide (3.0 mg and 4.5 mg) efficacy data
- REWIND (dulaglutide) and SUSTAIN-6 (semaglutide) — cardiovascular outcomes trials
- American Diabetes Association — Standards of Care in Diabetes (GLP-1 use in type 2 diabetes and cardiovascular disease)